Time to sell exosome therapies to patients? No.
Some stem cell clinics and related firms are looking for new ways to make profits and toward that goal a few have latched onto the legitimate buzz around exosome research.
What are exosomes?
Imagine if you could bubble up a pea-sized sphere off your skin full of good stuff without harming yourself and toss it over to your relative or friend like a mini-water balloon toss, whose skin would fuse with it and absorb the goodies in side, then becoming healthier.
Sounds like sci-fi at that imagined human scale, but cells do this kind of thing quite often. The cellular ‘water balloons’ are exosomes, tiny subcellular packages containing unique mixtures of various molecules including anything from RNA to proteins (check out this database of exosome contents, called ExoCarta).
Research shows that the cellular soup inside exosomes can influence cell behavior and there is a growing amount of legitimate work and excitement in this area. It’s not entirely clear that this cellular water balloon toss is always beneficial to other cells though.
A quick search on Clinicaltrials.gov found 95 study results, with the usual mix of relevant and not so relevant search results as well as more legit and less solid-looking listings, but overall this is a surprisingly large number of trials for this emerging area of biomedical research. You can see a map of trial locations below, with the U.S., Europe, and China leading the way.
Just based on the state of the science, I believe that exosome research is not to the point where anyone should be directly marketing it to consumers (or indirectly to physicians) to try to make money, but people are doing this anyway lately and it seems centered on the supposed benefits of exosomes made specifically from stem cells.
One of the more recent examples of unproven stem cell exosomes apparently being sold comes from the story of a paralyzed former cheerleader and coach, Chico Garcia, looking for hope. Garcia is reportedly going to get “exosomes” from stem cells at a price tag of $11,000. The news story is short on details, but it mentions a physician:
“Dr. Douglas Spiel at the center said the way it works is they take very small products from young stem cells. Think of them as individual protein factories. They go to dormant cells in the body and inject the protein. The goal is for the proteins to help repair tissues in parts of the body that are not responding. “
A website for Stem Cell Center of NJ features Spiel and exosome therapies. For instance, there’s this passage.
“Dr. Spiel believes in ongoing self-education and study since the field of Regenerative Medicine is constantly evolving. He regularly attends, lectures and provides hands-on instruction for the Boston BioLife conferences multiple times per year. Besides having his own practice, Dr. Spiel is also Medical Director of Kimera Corporation, which is an international company providing Exosomes based out of Miami, Florida.”
On the NJ Center site it is claimed that exosomes might help various conditions including baldness, ED, spinal cord injury, neuropathy, and possibly stroke, although in the stroke section it is described (perhaps a typo) as “exome therapy” instead of “exosome therapy.” The exome is the collection of exon sequences in the genome. In my view the content on that page risks giving patients the wrong idea that exosomes are some kind of proven panacea.
“Kimera Corporation” mentioned in this quote is probably Kimera Stem Cell Labs/Kimera Labs, which seems to market some stem cells and exosomes. Dr. Spiel is listed on the Kimera site as its CMO.
There are others out there selling unproven exosome therapies as well and I expect the number is growing. I personally doubt the effectiveness of unproven stem cell exosomes as a therapy for many conditions.
Also, there will be risks. Sometimes exosomes from one cell that end up as part of another cell, may negatively influence the health of the other cell. Multiply that by billions or trillions and you can envision possible tissue damage in a hypothetical scenario of things gone wrong. My understanding is that exosome therapies are drugs, requiring an IND from the FDA and should go through clinical trials before being marketed to patients.
The bottom line is that in my view exosomes shouldn’t be sold to patients today even as I hope that in future years exosome therapies of some kind will be proven safe and effective from proper clinical trials.